DIA£¨Data Independent Acquisition£©ÊÇÒ»ÏîÈÚºÏÁË´«Í³µ°°××éѧ“Äñǹ·¨”£¨shotgun£©ºÍÑ¡Ôñ·´Ó¦¼à²â/¶à·´Ó¦¼à²â£¨SRM/MRM£©¼¼ÊõÓÅÊƵÄȫеġ¢È«Ï¢Ê½Êý¾Ý·ÇÒÀÀµÐԲɼ¯¶¨Á¿¼¼Êõ¡£DIAÄܹ»½«É¨ÃèÇø¼äÄÚËùÓеÄëĶÎĸÀë×Ó¾­¹ý³¬¸ßËÙɨÃè²¢½øÐжþ¼¶ËéÁÑ£¬´Ó¶ø»ñµÃÍêÕûµÄëĶÎÐÅÏ¢¡£Ïà±È´«Í³µÄµ°°×ÖÊ×éѧ²ÉÓÃÊý¾ÝÒÀÀµ²É¼¯£¨DDA£©²ßÂÔ£¬DIA¼¼Êõ±ÜÃâÁËDDA²ßÂÔ¶ÔÓڸ߷á¶ÈëĶβɼ¯ºÍËéÁѵÄÆ«ÏòÐÔ£¬DIA¼¼Êõ¶ÔÓڵͷá¶ÈëĶεĶ¨Á¿¾ßÓÐÏÔÖøÓÅÊÆ¡£

|   DIA¼¼ÊõÔ­Àí

       DIA¼¼ÊõÊÇÏÈÀûÓó£¹æDDAÖÊÆ×¼ì²â¼¼Êõ·ÖÎö½¨Á¢Í¼Æ׿⣬֮ºó²ÉÓÃDIA·½·¨½øÐÐÖÊÆ×Êý¾Ý²É¼¯£¬´Ó¶øʵÏÖ¶ÔÑùÆ·Öе°°×ÖʵĶ¨ÐÔ¼°¶¨Á¿¡£²»Í¬ÓÚ´«Í³µÄDDA¼¼Êõ£¬DIA¼¼Êõ½«ÖÊÆ×Õû¸öȫɨÃ跶Χ·ÖΪÈô¸É¸ö¿É±ä´°¿Ú£¬¸ù¾Ým/z·Ö²¼ÃܶȼÆËãºÏÀíµÄ´°¿Ú¿í¶ÈºÍÊýÁ¿£¬¸ßËÙ¡¢Ñ­»·µØ¶Ôÿ¸ö´°¿ÚÖеÄËùÓÐÀë×Ó½øÐÐÑ¡Ôñ¡¢ËéÁÑ¡¢¼ì²â£¬¸Ã¼¼ÊõÎÞÐèÖ¸¶¨Ä¿±êëĶΣ¬É¨ÃèµãÊý¾ùÔÈ£¬¿ÉÒÔÎÞÒÅ©µØ»ñµÃÑù±¾ÖÐËùÓÐÀë×ÓµÄÈ«²¿ËéƬÐÅÏ¢£¬Êý¾ÝÀûÓöȴó´óÌá¸ß£¬È±Ê§Öµ¸üÉÙ¡£

|   DIA¼¼ÊõÓÅÊÆ

¡ñ   ¸ßͨÁ¿Óë¸ßÉî¶È£º²»ÊÜÑùÆ·¸öÊýµÄÏÞÖÆ£¬¿ÉÓÃÓÚ´ó¹æÄ£Ñù±¾ÊýÁ¿¼ì²â£¬Ç°´¦Àí²Ù×÷¹ý³Ì½ÏÉÙ£¬Ê¹Ñù±¾×î½Ó½üԭʼ״̬£¬Í¬Ê±²»ÊÜÑùÆ·Ìõ¼þÏÞÖÆ

¡ñ   ÌØÒìÐԺá¢ÁéÃô¶È¸ß£ºÈ«¾°Ê½É¨Ã裬Êý¾ÝÎÞÒÅ©£¬¶¨Á¿×¼È·ÐÔ´ó´óÌá¸ß

¡ñ   ÑϸñµÄÖÊÁ¿¿ØÖÆ£º¼ø¶¨Ó붨Á¿½á¹ûµÄ¿ÉÖظ´ÐÔ¸ü¸ß£¬Êý¾Ý¿É»ØËÝ

|   Ó¦ÓÃÁìÓò

¡ñ   ´ó¹æģѰÕÒ²îÒìµ°°×

¡ñ   16¸öÒÔÉÏÑùÆ·µÄ¶¨Á¿Ñо¿

¡ñ   ÉúÎï±êÖ¾Îïɸѡ

¡ñ   ѪҺµ°°×ÖÊ×éɸѡ

|   ¾­µä°¸Àý£ºDIAÓëDDAÔÚѪÇåµ°°××é·ÖÎöÖеļ¼Êõ¶Ô±È

      ¸ÃÎÄÏ×ÊÇһƪ±ê×¼DIA·ÖÎöÁ÷³ÌµÄÎÄÕ¡£ÊµÑéÁ÷³ÌÈçÏÂͼ£¬½¨Á¢¿ìËÙ¸ßЧµÄѪÇåµ°°×ÖÊ×éѧ·½·¨£¬Ñù±¾ÖƱ¸Î´½øÐг£¹æµÄÈ¥¸ß·á¶Èµ°°×²Ù×÷£¬Ö±½Ó¶ÔѪÇåÑùÆ·½øÐÐøÇУ¨Í¼2a£©¡£Í¨¹ýDDA¼¼ÊõÔÚÈý¸ö¼¼ÊõÖظ´ÖжÔδȥ¸ß·á¶Èµ°°×¡¢È¥¸ß·á¶Èµ°°×µÄÑùÆ·²â¶¨£»Í¨¹ý¸ßpH·´Ïà·ÖÁó½«Î´È¥¸ß·á¶Èµ°°×µÄÑùÆ··ÖΪ5¸öÁó·Ö£¬²¢ÓÃDDA·ÖÎöÿ¸öÁó·Ö¡£Í¨¹ý¶à´ÎDDA¼ø¶¨½¨Á¢ÑªÇå¹ãÆ׿⣬²¢¶ÔDIAÊý¾Ý½øÐзÖÎö¡£

ΪÁ˱ȽÏDIA·½·¨Ó봫ͳDDAµÄÌص㣬ͨ¹ý±ê×¼DDA·½·¨¶ÔÏàͬµÄѪÇåÑùÆ·½øÐÐÁËÈý´Î¼¼ÊõÖظ´£¬²¢Ê¹ÓÃÏàͬµÄ50·ÖÖÓÌݶȽøÐзÖÎö¡£½á¹û¶Ô±ÈÈçÏ£º

|   DIAÖØÏÖÐÔÓÅÓÚDDA

       ÔÚÈý¸öÖظ´ÖУ¬DDA¹²¼ø¶¨³ö202¸öµ°°×ÖʺÍ1495¸öëÄ£¬Ö»ÓÐ114£¨56%£©¸öµ°°×ÖʺÍ829£¨55%£©¸öëÄÔÚËùÓÐÖظ´ÖоùÓмø¶¨¡£¶øDIA£¨vDIA-2£©¼ø¶¨³ö375ÖÖµ°°×ÖʺÍ3238¸öëÄ£¬ÆäÖÐ325£¨87%£©¸öµ°°×ÖʺÍ2699£¨83%£©¸öëı»Öظ´¼ø¶¨¡£

       Í¨¹ýMaxQuantÈí¼þ·ÖÎöDDAģʽÏÂÊÕ¼¯µÄԭʼÊý¾Ý£¬¶Ô103¸öµ°°×ÖʽøÐÐÁ˶¨Á¿£¬ÆäÖÐ80¸öµ°°×ÖʵÄCV£¼10£¥£¬100¸öµ°°×ÖʵÄCV£¼20£¥¡£¶ø¶ÔÓÚDIA£¨vDIA-2£©£¬¶¨Á¿ÁË325ÖÖµ°°×ÖÊ£¬ÖÐÖµCVΪ7.8£¥£¬ÆäÖÐ193ÖÖµ°°×ÖʵÄCV£¼10£¥£¬256ÖÖµ°°×ÖʵÄCV£¼20£¥¡£

       ±¾ÎÄͨ¹ý¶Ô±ÈDIAÓëDDAÔÚ¼ø¶¨µ°°×ÊýÄ¿¡¢Öظ´ÐÔ¡¢¶¨Á¿×¼È·ÐÔ·½ÃæµÄÐÔÄÜÉÏ£¬ÌåÏÖÁËDIA¼¼ÊõµÄÓÅÊÆ£¬Ôڸ߶ȸ´ÔÓµÄѪÇåÑù±¾·ÖÎöÖÐDIA¼«´óÌá¸ßÁ˶¨Á¿·ÖÎöµÄ¿ÉÐŶÈ£¬Óиü¸ßµÄ¶¨Á¿×¼È·ÐԺͿÉÖظ´ÐÔ¡£

|   Ïà¹ØÎÄÏ×

[1]. Messner CB, Demichev V, Muenzner J, et al. The proteomic landscape of genome-wide genetic perturbations. Cell. 2023 Apr 27;186(9):2018-2034.e21.£¨¸¥ÀÊÎ÷˹·¿ËÀï¿ËÑо¿Ëù£©IF=64.5

[2]. Xu F, Yu EY, Cai X, et al. Genome-wide genotype-serum proteome mapping provides insights into the cross-ancestry differences in cardiometabolic disease susceptibility. Nat Commun. 2023 Feb 16;14(1):896.£¨Î÷ºþ´óѧÉúÃü¿ÆѧѧԺ£©IF=16.6

[3]. Qu L, Liu M, Zheng L,et al. Data-independent acquisition-based global phosphoproteomics reveal the diverse roles of casein kinase 1 in plant development. Sci Bull (Beijing). 2023 Aug 9:S2095-9273(23)00535-2.£¨ÉϺ£ÊÐÏÖ´úÖÖҵЭͬ´´ÐÂÖÐÐÄ£©IF=18.9

[4]. Lou R, Cao Y, Li S, et al. Benchmarking commonly used software suites and analysis workflows for DIA proteomics and phosphoproteomics. Nat Commun. 2023 Jan 6;14(1):94.£¨ÉϺ£¿Æ¼¼´óѧiHumanÑо¿Ëù£©IF=16.6

[5]. Niu L, Thiele M, Geyer PE, et al. Noninvasive proteomic biomarkers for alcohol-related liver disease. Nat Med. 2022 Jun;28(6):1277-1287.£¨ÅµºÍŵµÂ»ù½ð»áµ°°×ÖÊÑо¿ÖÐÐÄ£©IF=82.9

[6]. Yang F, Jia G, Guo J, et al. Quantitative Chemoproteomic Profiling with Data-Independent Acquisition-Based Mass Spectrometry. J Am Chem Soc. 2022 Jan 19;144(2):901-911.£¨±±¾©´óѧÉúÎïÓлúÓë·Ö×Ó¹¤³Ì½ÌÓý²¿ÖصãʵÑéÊÒ£©IF=15.0

[7]. Gebreyesus ST, Siyal AA, Kitata RB, et al. Streamlined single-cell proteomics by an integrated microfluidic chip and data-independent acquisition mass spectrometry. Nat Commun. 2022 Jan 10;13(1):37.£¨ÖÐÑëÑо¿Ôº£©IF=16.6

[8]. Fabienne Meier-Abt, Junyan Lu, Ester Cannizzaro, et al. The Protein Landscape of Chronic Lymphocytic Leukemia Blood. 2021 Dec 16;138(24):2514-2525.£¨ËÕÀèÊÀ´óѧҽԺ£©IF=20.3

[9]. Fabian Coscia 1 2, Sophia Doll 2, Jacob Mathias Bech, et al. A streamlined mass spectrometry-based proteomics workflow for large scale FFPE tissue analysis. J Pathol. 2020 May;251(1):100-112.£¨ÅµºÍŵµÂ»ù½ð»áµ°°×ÖÊÑо¿ÖÐÐÄ£©IF=7.3

[10].  Chongshu Jian 1, Jiajun Fu 2, Xu Cheng, et al. Low-Dose Sorafenib Acts as a Mitochondrial Uncoupler and Ameliorates Nonalcoholic Steatohepatitis. Cell Metab. 2020 May 5;31(5):892-908.e11.£¨Î人´óѧÈËÃñÒ½Ôº£©IF=29.0

[11].  Yangying Zhou, T Mamie Lih, Jianbo Pan, et al. Proteomic signatures of 16 major types of human cancer reveal universal and cancer-type-specific proteins for the identification of potential therapeutic targets. J Hematol Oncol. 2020 Dec 7;13(1):170.£¨Ô¼º²»ôÆÕ½ð˹ҽѧԺ²¡Àíѧϵ£©IF=28.5

[12].  Lin Lin, Jiaxin Zheng, Quan Yu, et al. High throughput and accurate serum proteome profiling by integrated sample preparation technology and single-run data independent mass spectrometry analysis. J Proteomics. 2018 Mar 1;174:9-16.£¨ÄÏ·½¿Æ¼¼´óѧ»¯Ñ§Ïµ£©